RC
Rovin Capital Portfolio holdings
AUM
$361M
1-Year Est. Return
12.81%
1 Year Est. Return
+12.81%
AUM
$330M
AUM Growth
+$19.4M
(+6.3%)
Holding
192
Top Buys
| 1 | +$9.31M | |
| 2 | +$7.17M | |
| 3 | +$6.37M | |
| 4 |
Schwab US Large-Cap Growth ETF
SCHG
|
+$4.22M |
| 5 |
Vanguard Total International Bond ETF
BNDX
|
+$1.36M |
Top Sells
| 1 | +$9.69M | |
| 2 | +$6.62M | |
| 3 | +$5.02M | |
| 4 |
iShares Core S&P US Value ETF
IUSV
|
+$4.77M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$3.46M |
Sector Composition
| 1 | Healthcare | 7.26% |
| 2 | Technology | 6.62% |
| 3 | Communication Services | 1.7% |
| 4 | Financials | 1.69% |
| 5 | Consumer Discretionary | 1.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Caterpillar
CAT
$280B
| $240K | 0.07% |
+618
|
|
||
177
Verizon
VZ
$174B
| $234K | 0.07% |
5,418
-87
|
|
||
178
Delta Air Lines
DAL
$43.9B
| $230K | 0.07% |
+4,668
|
|
||
179
Travelers Companies
TRV
$63.1B
| $226K | 0.07% |
844
|
|
||
180
Direxion Daily Healthcare Bull 3X Shares
CURE
$192M
| $213K | 0.06% |
2,700
+400
|
|
||
181
Gilead Sciences
GILD
$152B
| $213K | 0.06% |
1,925
-2,256
|
|
||
182
Johnson & Johnson
JNJ
$488B
| $207K | 0.06% |
+1,355
|
|
||
183
QuantumScape
QS
$7.8B
| $119K | 0.04% |
+17,700
|
|
||
184
Lucid Motors
LCID
$4.59B
| $67K | 0.02% |
+3,190
|
|
||
185
Compass Therapeutics
CMPX
$992M
| $35K | 0.01% |
13,495
|
|
||
186
Geron
GERN
$804M
| $24K | 0.01% |
17,270
|
|
||
|
ONCY
187
Oncolytics Biotech
ONCY
$104M
| $16K | ﹤0.01% |
20,620
|
|
||
188
AbbVie
ABBV
$404B
| – | – |
-1,133
|
|
||
189
Brown-Forman Class B
BF.B
$14B
| – | – |
-13,873
|
|
||
190
Campbell Soup
CPB
$8.73B
| – | – |
-11,793
|
|
||
191
Equifax
EFX
$25.9B
| – | – |
-1,351
|
|
||
|
192
iShares Core S&P US Value ETF
IUSV
$23.9B
| – | – |
-51,715
|
|